z-logo
Premium
Pharmacologic effects and physiologic disposition of delta 6a,10a dimethyl heptyl tetrahydrocannabinol (DMHP) in man
Author(s) -
Lemberger Louis,
McMahon Robert,
Archer Robert,
Matsumoto Ken,
Rowe Howard
Publication year - 1974
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1974154380
Subject(s) - delta 9 tetrahydrocannabinol , medicine , euphoriant , anesthesia , urine , supine position , endocrinology , cannabinoid , receptor , psychiatry
14 C‐DMHP (200 µg/70 kg man) was administered by the intravenous route to 3 healthy male casual marihuana smokers. Tachycardia occurred within 10 minutes and persisted for from 11 1/2 to 6 hours. Blood pressure fell slightly with time when subiects were supine, while standing for less than 1 minute resulted in marked hypotension. In these 3 subjects, except for dizziness on standing there were essentially no demonstrable psychologic effects, neither euphoria nor dysphoria. Subiects did, however, report symptoms similar to those after marihuana or Δ 9 ‐THC, including dry mouth, decreased salivation, and drowsiness. After intravenous dimethyl heptyl tetrahydrocannabinol (DMHP), plasma levels of total radioactivity and 14 C‐DMHP declined in a multiphasic fashion; the half‐life of the terminal phase for DMHP was 39 hours. Approximately 69% of the administered radioactive dose was recovered in 7 days. Radioactivity was excreted predominantly in the feces (58%) and to a lesser extent in urine (11%) during the 7 day collection period.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom